Skip to main content
main-content

ESMO Congress 2022 coverage

News and expert insight from the 2022 European Society for Medical Oncology Congress
Hope Rugo

12-09-2022 | ESMO 2022 | Conference coverage | Video

TROPiCS-02 shows sacituzumab govitecan OS benefit in HR+, HER2– advanced breast cancer

Hope Rugo outlines the latest results from the TROPiCS-02 trial of sacituzumab govitecan in hormone receptor-positive, HER2-negative advanced breast cancer and discusses where the antibody–drug conjugate fits into the treatment paradigm.

Joaquim Bellmunt

14-09-2022 | ESMO 2022 | Conference coverage | Video

Exploratory data suggest potential of epigenetic biomarkers in advanced UC

Joaquim Bellmunt outlines the latest analysis from the JAVELIN Bladder 100 trial pointing to a potential role for chromatin conformation loops as a biomarker of maintenance avelumab benefit in advanced urothelial cancer.

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

Jonathan Rosenberg

13-09-2022 | ESMO 2022 | Conference coverage | Video

Latest EV-103 update further supports enfortumab vedotin for untreated advanced UC

Jonathan Rosenberg presents data from a randomized noncomparative cohort of the EV-103 trial of enfortumab vedotin, investigating the agent alone or together with pembrolizumab as a first-line option for cisplatin-ineligible patients with advanced urothelial carcinoma.

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

Toni Choueiri

13-09-2022 | ESMO 2022 | Conference coverage | Video

COSMIC-313 points to first-line triplet option for advanced RCC

Toni Choueiri tells us about the COSMIC-313 trial evaluating the addition of cabozantinib to nivolumab plus ipilimumab in intermediate- or poor-risk patients with treatment-naïve, advanced renal cell carcinoma.

Enrique Grande Pulido

12-09-2022 | ESMO 2022 | Conference coverage | Video

IMvigor130 analysis highlights need to standardize PD-L1 expression assessment

Enrique Grande Pulido takes us through an exploratory analysis of the IMvigor130 trial of atezolizumab in metastatic urothelial cancer focusing on the differences in outcomes according to the assay used to assess PD-L1 expression, and highlights the clinical relevance of the findings.

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

More on thoracic cancers

Melissa Johnson

16-09-2022 | ESMO 2022 | Conference coverage | Video

Sotorasib outperforms docetaxel in previously treated KRAS-mutated NSCLC

Melissa Johnson provides an overview of the CodeBreaK 200 study pitting sotorasib against docetaxel in patients who have received prior treatment for non-small-cell lung cancer with KRAS G12C mutations.

Stay informed with Medicine Matters

Get the latest developments in breast, lung, & GU cancers delivered straight to your inbox


Medicine Matters conference coverage is brought to you in partnership with medwireNews